The centerpiece of the acquisition is Ohtuvayre, a treatment for chronic obstructive pulmonary disease that secured U.S. approval last year. The drug’s commercial launch has exceeded Wall Street ...

President Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S., but not immediately ...

When female athletes collapse on the playing field, they are less likely to be resuscitated than men: How gender differences ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...

The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Medicare drug ...

Technology will soon make it possible to develop cheap, widely accessible psychoactive substances that are not harmful in the ...

Hype around a Microsoft AI agent's ability to diagnose difficult cases misses the mark and overlooks real innovation, experts ...

This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and ...

The passage of President Trump's signature tax cut bill shows how the health care industry's influence is waning.

From my colleague Andrew Joseph: Novartis said today that Swiss regulators have approved its malaria medicine Coartem for newborns and young infants, extending a long-standing treatment to the ...

Pervasive stigma around cannabis use is leading some ER doctors to overdiagnose a rare marijuana-related syndrome.